NEW YORK (GenomeWeb News) — Clontech will stop selling its RNase H minus reverse transcriptase products as part of a settlement reached last week with Invitrogen.
Â
Invitrogen sued Clontech more than a decade ago for infringing two of its US patents — numbers 5,244,797 and 5,668,005 — that cover embodiments of the firm's reverse transcriptases. Invitrogen added two more of its US patents, numbers 6,063,608 and 5,405,776, to the suit later. All of the intellectual property relates to mutations that disable the RNase H activity of native reverse transcriptase
Â
The settlement came after an undisclosed jury decision last week in a federal district court in Maryland. As part of the settlement, Clontech agreed that Invitrogen's patents in the case are "valid and enforceable."
Â
Further details of the agreement were not disclosed.
Â
Clontech is a wholly owned subsidiary of Takara Bio.